X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The preclinical results showed that Comera’s caffeine-based SQore™ excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic (PK) parameters of ipilimumab when administered subcutaneously.
Lead Product(s): CLS-002,Ipilimumab
Therapeutic Area: Oncology Product Name: CLS-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
Comera announced favorable topline results of its SEQURUS-1 preclinical study in July, demonstrating supportive evidence of the safety of Comera’s lead caffeine-based proprietary SQore excipient when administered as a SQ biologic drug product formulation with a mAb.
Lead Product(s): Ipilimumab,Caffeine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
SQore is a caffeine-based excipient when administered as a subcutaneous and combination ipilimumab, a mAb therapy that works to activate the immune system by targeting CTLA-4 to treat melanoma, as a model protein.
Lead Product(s): Caffeine,Ipilimumab
Therapeutic Area: Oncology Product Name: SQore
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris.
Lead Product(s): CLS-001
Therapeutic Area: Gastroenterology Product Name: CLS-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner’s currently marketed medicine.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 09, 2022
Details:
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore™ platform. Intas will provide research funding with the option to acquire global rights of MabTas formulation.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: MabTas
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
